Glenmark Pharmaceuticals: Launches Winlevi® Cream For Acne Treatment In Major European Markets; First New Chemical Entity Launch In Europe; Enhances Dermatology Product Range With Direct Market Entries.

 11 Jun 2026 10:22 AM

Glenmark Pharmaceuticals: Launches Winlevi® Cream For Acne Treatment In Major European Markets; First New Chemical Entity Launch In Europe; Enhances Dermatology Product Range With Direct Market Entries.

Glenmark Pharmaceuticals: Investec maintains a Buy on Glenmark Pharmaceuticals with a Target Price of ₹2,750, citing confidence in 13–15% sales growth and 100bps margin expansion to FY30, strong growth in India and the US, innovation-led products contributing 30% of sales by FY30, and optionality from its innovation arm IGI following the AbbVie deal and planned annual IND filings from FY27.

 11 Jun 2026 08:59 AM

Glenmark Pharmaceuticals: Investec maintains a Buy on Glenmark Pharmaceuticals with a Target Price of ₹2,750, citing confidence in 13–15% sales growth and 100bps margin expansion to FY30, strong growth in India and the US, innovation-led products contributing 30% of sales by FY30, and optionality from its innovation arm IGI following the AbbVie deal and planned annual IND filings from FY27.

Glenmark: Company Aims For 13-15% Revenue Growth, Targets 23% EBITDA Margin By FY27, Focuses On Margin Growth And Strong Returns. Company Looks For Over 23% ROCE And 20%+ ROE While Keeping A Net Cash Position.

 09 Jun 2026 05:02 PM

Glenmark: Company Aims For 13-15% Revenue Growth, Targets 23% EBITDA Margin By FY27, Focuses On Margin Growth And Strong Returns. Company Looks For Over 23% ROCE And 20%+ ROE While Keeping A Net Cash Position.

Glenmark: Company Plans One IND Filing Each Year; Aims for Average Annual Investment of About $70 Million.

 09 Jun 2026 04:58 PM

Glenmark: Company Plans One IND Filing Each Year; Aims for Average Annual Investment of About $70 Million.

Glenmark Pharmaceuticals Limited: Aims To Grow Its Respiratory Products In FY27; Winlevi® Has Gained EU Approval With A Launch Planned For FY27, And Aumolertinib's Initial Launch Is Anticipated In H2 FY27.

 30 May 2026 03:07 PM

Glenmark Pharmaceuticals Limited: Aims To Grow Its Respiratory Products In FY27; Winlevi® Has Gained EU Approval With A Launch Planned For FY27, And Aumolertinib's Initial Launch Is Anticipated In H2 FY27.

GLENMARK PHARMA: Q4 CONS NET PROFIT 3B RUPEES VS 465M (YOY) || Q4 REVENUE 37.6B RUPEES VS 32.6B (YOY)

 29 May 2026 08:25 PM

GLENMARK PHARMA: Q4 CONS NET PROFIT 3B RUPEES VS 465M (YOY) || Q4 REVENUE 37.6B RUPEES VS 32.6B (YOY)

GLENMARK PHARMA: Q4 EBITDA 9.4B RUPEES VS 5.6B (YOY) || Q4 EBITDA MARGIN 25% VS 17.23% (YOY)

 29 May 2026 08:25 PM

GLENMARK PHARMA: Q4 EBITDA 9.4B RUPEES VS 5.6B (YOY) || Q4 EBITDA MARGIN 25% VS 17.23% (YOY)

Glenmark Pharma: Joint Venture IGI Introduces ISB 2301, A Novel Immune Cell Activator For Treating Various Solid Tumors.

 20 May 2026 04:25 PM

Glenmark Pharma: Joint Venture IGI Introduces ISB 2301, A Novel Immune Cell Activator For Treating Various Solid Tumors.

Glenmark Pharmaceuticals: Introduces Vancomycin Hydrochloride Injection In 500 MG And 1 G Vials In The U.S.; Product Matches Fresenius Kabi's Drug; Market Sales Hit $37.9 Million.

 18 May 2026 09:04 AM

Glenmark Pharmaceuticals: Introduces Vancomycin Hydrochloride Injection In 500 MG And 1 G Vials In The U.S.; Product Matches Fresenius Kabi's Drug; Market Sales Hit $37.9 Million.

Glenmark Pharma: U.S. FDA Approves 100 Mg Progesterone Vaginal Inserts, Drug Sales Hit About $59 Million Per Year

 09 Apr 2026 08:59 AM

Glenmark Pharma: U.S. FDA Approves 100 Mg Progesterone Vaginal Inserts, Drug Sales Hit About $59 Million Per Year

Glenmark Pharmaceuticals: Company Starts Direct U.S. Sales Of Ryaltris, Growing Its Innovative Product Line

 01 Apr 2026 05:39 PM

Glenmark Pharmaceuticals: Company Starts Direct U.S. Sales Of Ryaltris, Growing Its Innovative Product Line

GLENMARK PHARMACEUTICALS: CO LAUNCHES GLIPIQ® (SEMAGLUTIDE) IN INDIA || SETTING A NEW BENCHMARK IN AFFORDABILITY FOR GLP-1 THERAPY, WITH WEEKLY TREATMENT STARTING AT ₹325.

 21 Mar 2026 10:01 AM

GLENMARK PHARMACEUTICALS: CO LAUNCHES GLIPIQ® (SEMAGLUTIDE) IN INDIA || SETTING A NEW BENCHMARK IN AFFORDABILITY FOR GLP-1 THERAPY, WITH WEEKLY TREATMENT STARTING AT ₹325.

Glenmark Pharma: Glenmark Pharmaceuticals Inc. Launches Milnacipran Hydrochloride Tablets, A Generic Version Of Savella, In The U.S. Market Worth $103 Million

 19 Mar 2026 08:47 AM

Glenmark Pharma: Glenmark Pharmaceuticals Inc. Launches Milnacipran Hydrochloride Tablets, A Generic Version Of Savella, In The U.S. Market Worth $103 Million

Glenmark Pharma: Gets US FDA Approval For Fluticasone Nasal Spray Aiming At $384 Million OTC Market.

 19 Mar 2026 08:40 AM

Glenmark Pharma: Gets US FDA Approval For Fluticasone Nasal Spray Aiming At $384 Million OTC Market.

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Is Set To Release Potassium Phosphates Injection In The US, With Annual Sales Nearing USD 50.7 Million.

 16 Mar 2026 08:55 AM

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Is Set To Release Potassium Phosphates Injection In The US, With Annual Sales Nearing USD 50.7 Million.

Glenmark Pharmaceuticals: HSBC maintains Buy on Glenmark Pharmaceuticals with Target Price Rs 2,600 (raised), citing USFDA approval of gFlovent 44mcg inhaler improving US sales trajectory, with learnings aiding gFlovent 110mcg ANDA review, and consistent new US approvals seen as the key catalyst.

 11 Mar 2026 09:05 AM

Glenmark Pharmaceuticals: HSBC maintains Buy on Glenmark Pharmaceuticals with Target Price Rs 2,600 (raised), citing USFDA approval of gFlovent 44mcg inhaler improving US sales trajectory, with learnings aiding gFlovent 110mcg ANDA review, and consistent new US approvals seen as the key catalyst.

Glenmark Pharma: Glenmark Specialty Wins U.S. FDA Approval For Fluticasone Propionate Inhalation Aerosol, 44 Mcg Per Actuation, With 180-Day Exclusive Generic Competition. Annual Sales Reach About USD 520 Million

 04 Mar 2026 08:44 AM

Glenmark Pharma: Glenmark Specialty Wins U.S. FDA Approval For Fluticasone Propionate Inhalation Aerosol, 44 Mcg Per Actuation, With 180-Day Exclusive Generic Competition. Annual Sales Reach About USD 520 Million

Glenmark Pharmaceuticals: Plans Launch Of Sodium Phosphates Injection USP In Three Forms Starting April 2026, With An Expected Market Size Of $66.8 Million

 27 Feb 2026 09:21 AM

Glenmark Pharmaceuticals: Plans Launch Of Sodium Phosphates Injection USP In Three Forms Starting April 2026, With An Expected Market Size Of $66.8 Million

Glenmark Pharma: Plans To Achieve 115 Days Of Net Working Capital By March '26, Currently At About 110 Days, And Aims To Have Zero Gross Debt By March '26. The Company Expects Annual Capital Expenditure Of INR 700-800 Crores, With INR 800 Crores Slated For Next Year Mainly For Plant Expansion And In-Licensing.

 03 Feb 2026 09:01 AM

Glenmark Pharma: Plans To Achieve 115 Days Of Net Working Capital By March '26, Currently At About 110 Days, And Aims To Have Zero Gross Debt By March '26. The Company Expects Annual Capital Expenditure Of INR 700-800 Crores, With INR 800 Crores Slated For Next Year Mainly For Plant Expansion And In-Licensing.

Glenmark: Expects Strong End To FY26 And Good Start To "Glenmark 3.0" Growth Journey In 2027, Aiming To Meet Overall Goals. Company Targets Sustainable EBITDA Margin Of 23% For This Year and Coming Quarters, Expecting Significant Margin Increase From FY28 Due To New Innovations

 03 Feb 2026 09:01 AM

Glenmark: Expects Strong End To FY26 And Good Start To "Glenmark 3.0" Growth Journey In 2027, Aiming To Meet Overall Goals. Company Targets Sustainable EBITDA Margin Of 23% For This Year and Coming Quarters, Expecting Significant Margin Increase From FY28 Due To New Innovations